BeiGene

Membership Level

Diamond

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,000+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market an internally-discovered product, BRUKINSA® (zanubrutinib) in the United States. To learn more about BeiGene, visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

BeiGene: Blood Cancer Has No Borders, Neither Do We: https://youtu.be/UUoKZYigazk

More information:

• Prescribing Information
• Dosing and Administration
• Patient Support
• Learn More about BeiGene
• BeiGene Corporate Brochure
• Brukinsa Branded HCP CVA
• Brukinsa Patient Brochure
• Dosing and Administration Guide
• Large Format PI (Digital) PDF
• myBeiGene and AssistPoint
• myBeiGene Enrollment Form
• myBeiGene HCP Brochure
• myBeiGene ONA Bio Sheet
• myBeiGene Patient Brochure
• Ordering Info and Distributor Sheet

Click the link to view BeiGene’s activities and presentations presented this year during the 25^th European Hematology Association (EHA) Virtual Congress that took place on June 11-14. http://ir.beigene.com/news-releases/news-release-details/beigene-presents-clinical-data-zanubrutinib-and-tislelizumab?loc=US